RhumbLine Advisers’s Jade Biosciences, Inc. Common Stock JBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $445K | Buy |
44,570
+43,920
| +6,757% | +$439K | ﹤0.01% | 2755 |
|
|
2025
Q1 | $57.1K | Buy |
650
+262
| +68% | +$23K | ﹤0.01% | 3540 |
|
|
2024
Q4 | $36K | Buy |
388
+9
| +2% | +$836 | ﹤0.01% | 3721 |
|
|
2024
Q3 | $27.7K | Sell |
379
-52
| -12% | -$3.8K | ﹤0.01% | 3772 |
|
|
2024
Q2 | $25K | Buy |
431
+13
| +3% | +$755 | ﹤0.01% | 3832 |
|
|
2024
Q1 | $432K | Buy |
418
+14
| +3% | +$14.5K | ﹤0.01% | 2756 |
|
|
2023
Q4 | $320K | Buy |
404
+4
| +1% | +$3.17K | ﹤0.01% | 2929 |
|
|
2023
Q3 | $190K | Buy |
400
+29
| +8% | +$13.8K | ﹤0.01% | 3187 |
|
|
2023
Q2 | $223K | Sell |
371
-52
| -12% | -$31.2K | ﹤0.01% | 3186 |
|
|
2023
Q1 | $298K | Buy |
423
+16
| +4% | +$11.3K | ﹤0.01% | 2617 |
|
|
2022
Q4 | $417K | Buy |
407
+3
| +0.7% | +$3.07K | ﹤0.01% | 2554 |
|
|
2022
Q3 | $234K | Buy |
404
+27
| +7% | +$15.6K | ﹤0.01% | 2838 |
|
|
2022
Q2 | $206K | Buy |
+377
| New | +$206K | ﹤0.01% | 2916 |
|